Ensifentrine Market Summary

Key Factors Driving Ensifentrine Growth

1) First novel inhaled COPD mechanism approved in >20 years

The biggest growth driver is differentiation. In June 2024, the U.S. FDA approved Ohtuvayre as the first inhaled product with a novel mechanism for COPD maintenance treatment in more than two decades. It works as a dual PDE3/PDE4 inhibitor, providing both:

• Bronchodilation (PDE3 inhibition)
• Non-steroidal anti-inflammatory effects (PDE4 inhibition)

This differentiates it from traditional LABA/LAMA/ICS therapies and positions it as an add-on therapy for symptomatic COPD patients still experiencing dyspnea/exacerbations.

2) Strong pivotal trial efficacy supports physician adoption

Approval was backed by the Phase III ENHANCE-1 and ENHANCE-2 trials, where ensifentrine showed meaningful clinical benefits:

• Significant improvement in lung function (FEV1)
• Reduced COPD exacerbation rates by ~40% in ENHANCE-1 and ~43% in ENHANCE-2 vs placebo
• Improved respiratory symptoms and quality-of-life scores

These outcomes are highly relevant because exacerbation reduction directly lowers hospitalization burden in COPD.

3) Extremely strong commercial launch trajectory

Launch execution has exceeded expectations:

• $42.3M net sales in FY 2024 (despite launch beginning only in August 2024)
• $36.6M in Q4 2024 alone
• 16,000+ prescriptions filled in 2024
• 3,500+ unique prescribers by year-end 2024

This showed unusually fast early adoption for a newly launched respiratory product.

4) 2025 growth acceleration has been even stronger

Momentum accelerated sharply in 2025:

• $71.3M net sales in Q1 2025 (+95% QoQ vs Q4 2024)
• ~25,000 prescriptions filled in Q1 2025 alone
• More than 4,600 unique prescribers
• Prescriptions filled through Feb-2025 already exceeded all of Q4 2024

Verona also stated ~55% of Tier-1 target HCPs had already prescribed Ohtuvayre, suggesting strong pulmonologist adoption.

Ensifentrine Recent Developments

• In April 2026, Nuance Pharma announced that CHEST, the official journal of the American College of Chest Physicians, has published results from the Phase III ENHANCE-CHINA trial evaluating OHTUVAYRE (ensifentrine) in chronic obstructive pulmonary disease ("COPD").

“Ensifentrine Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Ensifentrine for approved indication like Chronic obstructive pulmonary disease; as well as potential indication like Asthma, Bronchiectasis, and Cystic fibrosis in the 7MM. A detailed picture of Ensifentrine’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Ensifentrine for approved and potential indications. The Ensifentrine market report provides insights about Ensifentrine’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Ensifentrine performance, future market assessments inclusive of the Ensifentrine market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Ensifentrine sales forecasts, along with factors driving its market.

Ensifentrine Drug Summary

Ensifentrine is a first-in-class, inhaled dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor developed by Verona Pharma plc for the maintenance treatment of Chronic Obstructive Pulmonary Disease. By simultaneously inhibiting PDE3 and PDE4 enzymes in the lungs, ensifentrine delivers both bronchodilatory and anti-inflammatory effects, helping improve lung function while reducing exacerbations. Administered via nebulization, the drug demonstrated significant improvements in FEV1, symptom scores, and reductions in moderate-to-severe COPD exacerbations in the pivotal ENHANCE-1 and ENHANCE-2 Phase III trials. In 2024, it became the first novel inhaled mechanism approved for COPD maintenance treatment in more than two decades when the U.S. Food and Drug Administration approved it under the brand name Ohtuvayre, positioning it as an important new treatment option for patients with inadequately controlled COPD. The report provides Ensifentrine’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Ensifentrine Market Report

The report provides insights into:

• A comprehensive product overview including the Ensifentrine MoA, description, dosage and administration, research and development activities in approved indications like Chronic obstructive pulmonary disease; as well as potential indication like Asthma, Bronchiectasis, and Cystic fibrosis.
• Elaborated details on Ensifentrine regulatory milestones and other development activities have been provided in Ensifentrine market report.
• The report also highlights Ensifentrine‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Ensifentrine market report also covers the patents information, generic entry and impact on cost cut.
• The Ensifentrine market report contains current and forecasted Ensifentrine sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Ensifentrine market report also features the SWOT analysis with analyst views for Ensifentrine in approved and potential indications.

Methodology

The Ensifentrine market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ensifentrine Analytical Perspective by DelveInsight

• In-depth Ensifentrine Market Assessment

This Ensifentrine sales market forecast report provides a detailed market assessment of Ensifentrine for approved indication like Chronic obstructive pulmonary disease; as well as potential indication like Asthma, Bronchiectasis, and Cystic fibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Ensifentrine sales data uptil 2034.

• Ensifentrine Clinical Assessment

The Ensifentrine market report provides the clinical trials information of Ensifentrine for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Ensifentrine Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Ensifentrine Market Potential & Revenue Forecast

• Projected market size for the Ensifentrine and its key indications
• Estimated Ensifentrine sales potential (Ensifentrine peak sales forecasts)
• Ensifentrine Pricing strategies and reimbursement landscape

Ensifentrine Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Ensifentrine Market positioning compared to existing treatments
• Ensifentrine Strengths & weaknesses relative to competitors

Ensifentrine Regulatory & Commercial Milestones

• Ensifentrine Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Ensifentrine Clinical Differentiation

• Ensifentrine Efficacy & safety advantages over existing drugs
• Ensifentrine Unique selling points

Ensifentrine Market Report Highlights

• In the coming years, the Ensifentrine market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Ensifentrine companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Ensifentrine’s dominance.
• Other emerging products for Chronic obstructive pulmonary disease; as well as potential indication like Asthma, Bronchiectasis, and Cystic fibrosis are expected to give tough market competition to Ensifentrine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Ensifentrine in approved and potential indications.
• Analyse Ensifentrine cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Ensifentrine sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Ensifentrine in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Ensifentrine? How strong is Ensifentrine’s clinical and commercial performance?
• What is Ensifentrine’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease; as well as potential indication like Asthma, Bronchiectasis, and Cystic fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ensifentrine Manufacturers?
• What are the key designations that have been granted to Ensifentrine for approved and potential indications? How are they going to impact Ensifentrine’s penetration in various geographies?
• What is the current and forecasted Ensifentrine market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Ensifentrine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Ensifentrine for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Ensifentrine? What is the duration of therapy and what are the geographical variations in cost per patient?